EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia

Wataru Aoki, Yoshifumi Uwamino iD, Hiroaki Kubota iD, Yuka Kamoshita, Rika Inose, Mika Nagata, Ho Namkoong, Hiromichi Matsushita

Antimicrobial Agents and Chemotherapy · 05.11.2025 · 69 (11)

DOI: 10.1128/aac.00755-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.11.2025. Verfasst von Wataru Aoki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory, Keio University Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Aztreonam, Anti-Bacterial Agents, Cephalosporins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated the in vitro activity of aztreonam-nacubactam (ATM-NAC) and cefepime-nacubactam (FEP-NAC) against 53 clinical isolates of Stenotrophomonas maltophilia from blood cultures. Minimum inhibitory concentrations (MICs) were determined via broth microdilution. While ATM-NAC showed more significant MIC reduction, FEP-NAC also remarkably decreased MICs, despite cefepime being a substrate for L1 β-lactamase. These findings suggest the potential of β-lactam–NAC combinations as promising alternatives, warranting further in vivo studies to confirm clinical applicability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stenotrophomonas maltophiliaAztreonamAnti-Bacterial AgentsCephalosporinsCefepimeMicrobial Sensitivity TestsHumansGram-Negative Bacterial Infectionsbeta-LactamasesDrug Combinations

Stichwörter der Autor:innen

Stenotrophomonas maltophilianacubactam

Substanzen

CefepimeAztreonamAnti-Bacterial AgentsCephalosporinsbeta-LactamasesDrug Combinations

Autor:innen und Institutionen

  • Clinical Laboratory, Keio University Hospital, Tokyo, Japan.
  • Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Department of Microbiology, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.

ORCID-Profile: Yoshifumi Uwamino, Hiroaki Kubota

Förderung

  • Japan Science and Technology Agency

Zitieren

APA

Aoki, W., Uwamino, Y., Kubota, H., Kamoshita, Y., Inose, R., Nagata, M., Namkoong, H., & Matsushita, H. (2025). Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy, 69(11). https://doi.org/10.1128/aac.00755-25

Vancouver

Aoki W, Uwamino Y, Kubota H, Kamoshita Y, Inose R, Nagata M, et al. Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy. 2025;69(11). doi:10.1128/aac.00755-25

BibTeX
@article{Aoki2025,
  author = {Aoki, Wataru and Uwamino, Yoshifumi and Kubota, Hiroaki and Kamoshita, Yuka and Inose, Rika and Nagata, Mika and Namkoong, Ho and Matsushita, Hiromichi},
  title = {Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {11},
  doi = {10.1128/aac.00755-25}
}
Kostenlos starten →